Sneak Previews

I pick these special situations from those presented to me each month by my network of brokers, market makers, PR companies, investment bankers, venture capitalists, & key people in various industries. My primary criterion is my opinion of the stock's potential to double or better in the next six to 12 months.

Once a Sneak, a company becomes a candidate for the "Situation of the Month" coverage in a future issue. Our decision concerning which to cover in a more detailed way is based on what we find in continuing investigation. I may give special attention to a Sneak I did a year ago, or one from the last issue; do not attach significance to timing.

I will, however, do updates on those Sneaks I continue to follow, either in the "Update Briefs" section of the newsletter, in our planned e-mail updates, or in "Larry Oakley's Opinion," or "Larry Oakley's Daily Comment" sections of WallStreetCorner.

While Sneaks are preliminary recommendations, do not use them for investment decisions unless you decide on the basis of facts you uncover in your own investigation. Keep in mind that the codes listed after each Sneak are preliminary, reflecting my first impression. They are subject to change based on further investigation.

Codes: At the end of each Sneak Preview & Update, there are three codes. They have a rating from 1 to 10. Those numbers reflect my personal opinion. Please -- do not take action based on my opinion alone. Do four things before taking action: (1) Read my original writeup to get an overall feel; (2) Get the latest 10-Q, 10-K, corporate profile, & news releases; you can access them at www.WallStreetCorner.com by using "Financial Navigator;" (3) Study them; & (4) Call a key member of management to get a final impression. If anything bothers you regarding that call, pass. There are lots of situations. Do not invest unless everything about a situation feels good to you.

"R" stands for "Risk Rating." A "1" means I view the situation as having an extreme amount of risk. A "10" means very low risk -- a much sounder, more financially stable situation. You'll see hardly any with a "1" or "10" rating. I chose "10" to mean lowest risk so the higher the number after each of the three codes, the more favorable the rating.

"M" stands for "Midterm Appreciation Potential." A "1" means I view the situation as having a small degree of midterm ("mid-term" is six to 12 months) potential. A "10" means really outstanding midterm potential.

"L" stands for "Long-term Appreciation Potential." A "1" means I view the situation as having a small degree of long-term ("long-term" is over one year) potential. A "10" means really outstanding long-term potential.

Genetronics Biomedical Ltd. (AMEX & Toronto/GEB) is the technology leader in what is called electroporation, the application of brief controlled pulses of electric fields to cells, causing pores to open in the cell membrane. This is the basis of transdermal drug delivery -- a method of delivering drugs without using needle injection. This proprietary drug & gene delivery system enables cellular therapeutic intervention to help patients with catastrophic illnesses & other serious conditions. GEB operates through its wholly owned subsidiary Genetronics, Inc. in San Diego. On 10/6/98, it entered into comprehensive license & development agreements with Ethicon, Inc., a Johnson & Johnson company (J&J's market cap is well over $120 billion) involving its electroporation therapy treatment of cancer.

On 3/17/99, it received approval to market its MedPulserR electroporation device (used in the treatment of solid tumors) throughout the nations of the European Union, an area with a population of over 366 million; if one includes the European Free Trade Associations & the former Eastern Bloc countries which recognize the ECC approval, the population is over 583 million.

The applications for GEB's emerging technology include not only oncology & transdermal drug delivery, but dermatology, gene therapy & delivery, & vascular therapy -- all five multi-billion dollar markets. The potential is rather extensive. For example, in its interim Phase II clinical trial for the treatment of squamous cell carcinoma of the head & neck, 64% of the 42 tumors treated either disappeared completely, or reduced in size by at least 50%. The 33 patients involved had advanced head & neck cancer where conventional therapies (radiation, chemotherapy, or surgery) had failed. The treatment that worked involved a combination of electroporation & the anti-cancer drug bleomycin.

I like the fact that GEB does not develop drugs or discover genes. Former CEO Lois Crandell says "What we do is deliver pharmaceutical drugs or beneficial genes with new systems that are proving to be safe, efficient, & superior to any other methods available." Its systems are protected by a portfolio of 137 patents issued or pending -- a formidable barrier to competition. GEB has been funded through such placements as the $12.5 million private placement of 4,187,500 special warrants at $3 it completed in 6/99, & management expects to move to profitable operation sometime in 2001. Call Clarke L. Galvin, manager IR @ 888-289-4363 or 619-597-6006, fax 619-597-0119 or 858-410-3395, e-mail ir@genetronics.c-om, or write 11199 Sorrento Valley Rd., San Diego, CA 92121-1334. www.genetronics.com [R-6; M-7; L-8]

Global Entertainment Holdings/ Equities, Inc. (OTC Bulletin Board/GAMM) is a holding company for technology-based businesses in the online gaming sector. It provides financial advisory services to its subsidiaries (emerging companies in Internet gaming related businesses, software development, licensing services, & web publishing), including merger & acquisition, debt & equity investment, & general investment banking services. GAMM's strategy: Acquire software licensing agreements, provide value added website hosting services, develop online products, & expand its market reach into web-based content publishing.

GAMM derives revenue from three main sources; (1) licensing fees; (2) monthly web site hosting & maintenance fees; & (3) royalties & advertising. It anticipates generating additional future revenue through acquisitions in vertical markets, with particular focus in land-

...continued on next page, click here

Disclaimer: The public companies featured in the Research Reports or Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com (WSC) are our regular clients. Each such client, as of 12/1/2009, pays a modest cash fee for our three-month trial period, & on occasion may provide us with a negotiated number of Form 144 restricted shares as an incentive for our service. We may accept free-trading shares, but we usually hold such shares for the long pull – we do not engage in trading. Such fees are disclosed as part of the Research Report or Corporate Profile prepared & posted on the particular client company involved. The basic coverage provided to such clients primarily includes the preparation of their Research Report or Corporate Profile, posting it here at WallStreetCorner.com, & the distribution of email alerts to our international database of investors and financial professionals when their Report or Profile is initially posted, & each time their Report or Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Report or Profile & issue an additional email alert to our totally opt-in email database (as of December 2009, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Research Report or Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company & want the exposure afforded at WallStreetCorner.com, email Larry Oakley at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Research Reports or Corporate Profiles, & in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, &/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such a call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Examine the company’s latest financial information usually available on the company’s web site, and consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," “Comment,” and "Bold Ventures" columns, or in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Research Reports & Corporate Profiles plus the email distributions that are a part of the client’s package. On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: “Click here to access our Special Emerging Growth Situations.” See the introductory portion of that special section for additional information regarding the material covered there. The service provided to our readers here at WallStreetCorner is on an "as is" basis only. Neither we, nor any licensor or third party provider of any component of the service or of any information delivered as part of the service, makes, & each expressly disclaims, any representation or warranty of any kind, whether expressed, implied, or arising out of course of dealing or usage, including without limitation any warranty of fitness for a particular purpose, noninfringement, noninterference with data, availability, accuracy, or that the service is error-free or secure. The service occasionally contains information provided by one or more third party persons or firms or other third party data providers. We do not control & are not responsible for the information provided by any such third party provider. We specifically are not responsible for any damages caused by non-delivery, delayed delivery, or the misdirected delivery of an email Alert, update, editorial, Special Situation coverage, or other information, inaccurate or incomplete information in an Alert, update, editorial, Special Situation coverage, or other information, or your reliance on or use of any Alert, update, editorial, Special Situation coverage, or other information. We assume no responsibility for the timeliness, deletion, mis-delivery, or accuracy of any editorials, Research Reports, Corporate Profiles, Special Situation coverage, or any & all other content at this site. In no event may we, or any licensor or third party provider of any component of our service or of any information delivered as part of the service, be liable for any consequential, indirect, special, exemplary, punitive, or similar damages arising from or related to the service, even if advised of the possibility of such.

WallStreetCorner.com
WallStreetCorner.com, Inc.